Skip to main content

RT @synovialjoints: Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a hi

Nov 14, 2022 10:05 am
Social Author Name
Dr. Antoni Chan
Tweet Content
Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a history of artherosclerotic CV disease (ASCVD). CV risk (MACE-8 with HF +VTE) was higher in the Tofa 10mg bd vs TNFi. Buch M #L06 https://t.co/lFXl2ywbZe #ACR22 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×